Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report


Werte in diesem Artikel
Aktien

76.28 EUR 0.36 EUR 0.47 %

Filing of the 2023 U.S. Form 20-F and French "Document d’Enregistrement Universel” containing the Annual Financial Report

Werbung

Paris, February 23, 2024. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its "Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

These documents are available on the company’s website: https://www.sanofi.com/en/investors/reports-and-publications/financial-reports-and-regulated-information

In addition, the Form 20-F is available on the website of the SEC (www.sec.gov) and the "Document d’Enregistrement Universel” is available on the website of the AMF (www.amf-france.org). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

Werbung

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com

Investor Relations
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.com
Felix Lauscher | + 1  908  612 7239 | felix.lauscher@sanofi.com
Tarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Werbung


 

Attachment


Aktuelle Sanofi Aktie News

Werbung

Sanofi Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sanofi nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
06.07.26 Sanofi Neutral Goldman Sachs Group Inc.
06.07.26 Sanofi Neutral JP Morgan Chase & Co.
02.07.26 Sanofi Buy Jefferies & Company Inc.
15.06.26 Sanofi Buy Deutsche Bank AG
09.06.26 Sanofi Buy Deutsche Bank AG